Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines.
暂无分享,去创建一个
[1] F M Muggia,et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Michael J Sailor,et al. Biomimetic amplification of nanoparticle homing to tumors , 2007, Proceedings of the National Academy of Sciences.
[3] M. Imai,et al. Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. , 2008, Cancer research.
[4] S Moein Moghimi,et al. Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. , 2006, Anti-cancer agents in medicinal chemistry.
[5] Zhuang Liu,et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. , 2008, Cancer research.
[6] H. Dai,et al. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. , 2008, Molecular immunology.
[7] S. Moghimi,et al. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug , 2008, Expert opinion on drug delivery.
[8] S. Moghimi,et al. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance , 2002, FEBS letters.
[9] B. Nilsson,et al. Complement and coagulation: strangers or partners in crime? , 2007, Trends in immunology.
[10] Dipak K. Sarker,et al. Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. , 2006, Journal of nanoscience and nanotechnology.
[11] Janos Szebeni,et al. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. , 2005, Toxicology.
[12] G. Fleuren,et al. Tumor-Specific Inhibition of Membrane-Bound Complement Regulatory Protein Crry with Bispecific Monoclonal Antibodies Prevents Tumor Outgrowth in a Rat Colorectal Cancer Lung Metastases Model , 2004, Cancer Research.
[13] John D. Lambris,et al. Modulation of the anti-tumor immune response by complement , 2008, Nature Immunology.
[14] Stephen Tomlinson,et al. Complement function in mAb-mediated cancer immunotherapy. , 2004, Trends in immunology.
[15] Sai T Reddy,et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.
[16] Janos Szebeni,et al. Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[17] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[18] John D Lambris,et al. Complement-targeted therapeutics , 2007, Nature Biotechnology.
[19] J Szebeni,et al. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.
[20] Poloxamer-188 revisited: a potentially valuable immune modulator. , 1996, Journal of the National Cancer Institute.